The move could result in changes to guidelines that currently prohibit cornea donations from gay or bisexual men who have had sex with another man in the last 5 years of their life. There's no indication as to whether other queer communities, such as transgender women or nonbinary donors, will be impacted.
Therapeutic has fewer adverse effects in patients with POAG, OHT.
According to company officials,the new image modality provides additional retinal visualization to our customers as they manage their patient’s treatment and ongoing care.
The day helps to bring focus and awareness to risk factors for early vision loss associated with smoking.
According to the company, the Preservative Freedom Coalition will put the topic of preservative-free eye care in focus through education to eye care professionals and patients.
The photochromic lenses, available in Singapore, provide added protection against intensive sunlight and can darken outdoors and fade back to transparent indoors.
New option a potential treatment for patients diagnosed with dry eye disease.
In a Wilmer Eye Institute study, in mice and human cell models, the drug 32-134D lowered protein levels known to contribute to diabetic macular edema and diabetic retinopathy
Data supports ANX007 as the first complement therapy to preserve visual acuity, achieving statistically significant protection, but reduction in rate of geographic atrophy lesion growth did not reach statistical significance.
The research conducted at the Wayne State University School of Medicine implies that VCAM1 antagonism could be a promising therapeutic strategy for proliferative retinal disorders.
Dual therapy may slow the progression of condition.
The iPredict AI Eye Screening System will provide a fully automated age-related macular degeneration (AMD) screening report in less than 60 seconds.
According to the company, its latest laser recently received FDA clearance and CE mark approval.
According to the company, THR-149 is currently being evaluated in the KALAHARI Phase 2, Part B clinical trial as a potential treatment for patients who respond suboptimally to anti-VEGF, the standard of care for treatment of DME.
Medical, surgical management can be important tools.
While the 6-weekly regimen was less effective in improving the clinical activity score or exophthalmos than the higher dose regimen, it is an acceptable treatment choice for patients with marginal or lower clinical activity scores.
The project, a collaboration with researchers from the University of Maryland, holds promise for advancing new and more tolerable drug treatments for common chronic blinding eye diseases, including glaucoma and macular degeneration.
According to the company, AG-73305 was found to be safe and tolerable with no severe adverse effects after a single intravitreal injection of 0.5 mg and 1 mg in patients diagnosed with diabetic macular edema.
According to the company, topical administration is capable of delivering metformin to choroid, RPE, and retina.
SLT shows promise as treatment for millions of Africans with glaucoma.
Louis R. Pasquale, MD, FARVO, will be presented the award by previous winner Robert N. Weinreb, MD.
According to the company, the study has now reached its goal of 300 patients enrolled to evaluate ILUVIEN as a first line, baseline therapy for DME.
The investigative team wanted to provide physicians with reference guidelines to aid in the prevention and control of myopia.
Macular hole closure results from this novel treatment.
Instrumentation recreates properties of the myopic eye to test lenses that prevent visual decline.
According to the company, study results show sustained reductions in both IOP and glaucoma medication use in mild-moderate primary open angle glaucoma patients treated with a procedure enabled with the OMNI Surgical System technology.
In a recent update, the CDC has noted an additional death, bringing the death toll up to 4, with numerous counts of vision loss across the US.
Data demonstrate a reduction in the loss of retinal pigmented epithelial and photoreceptor cells.
The two companies have announced an exclusive agreement for Polifarma to commercialize AVT06, the proposed biosimilar to Eylea, in Turkey.
.png "Optometry Times"){kind=logo}
